Affiliations 

  • 1 Institute of Pharmaceutical Science, Faculty of Life Sciences & Medicine, King's College London, London, UK
  • 2 Max Planck Institute for Polymer Research, Mainz, Germany
  • 3 Institute of Liver Studies, King's College London University and King's College Hospital, London, UK
  • 4 Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London, UK
  • 5 Comprehensive Cancer Centre, King's College London, London, UK
  • 6 Institute of Pharmaceutical Science, Faculty of Life Sciences & Medicine, King's College London, London, UK. khuloud.al-jamal@kcl.ac.uk
Nat Nanotechnol, 2024 Feb 16.
PMID: 38366223 DOI: 10.1038/s41565-023-01585-y

Abstract

Extracellular vesicles (EVs) derived from mesenchymal stem cells are promising nanotherapeutics in liver diseases due to their regenerative and immunomodulatory properties. Nevertheless, a concern has been raised regarding the rapid clearance of exogenous EVs by phagocytic cells. Here we explore the impact of protein corona on EVs derived from two culturing conditions in which specific proteins acquired from media were simultaneously adsorbed on the EV surface. Additionally, by incubating EVs with serum, simulating protein corona formation upon systemic delivery, further resolved protein corona-EV complex patterns were investigated. Our findings reveal the potential influences of corona composition on EVs under in vitro conditions and their in vivo kinetics. Our data suggest that bound albumin creates an EV signature that can retarget EVs from hepatic macrophages. This results in markedly improved cellular uptake by hepatocytes, liver sinusoidal endothelial cells and hepatic stellate cells. This phenomenon can be applied as a camouflage strategy by precoating EVs with albumin to fabricate the albumin-enriched protein corona-EV complex, enhancing non-phagocytic uptake in the liver. This work addresses a critical challenge facing intravenously administered EVs for liver therapy by tailoring the protein corona-EV complex for liver cell targeting and immune evasion.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.